Prestige BioPharma Limited

KSE 950210.KS

Prestige BioPharma Limited Debt to Equity Ratio for the year ending June 30, 2024: 0.20

Prestige BioPharma Limited Debt to Equity Ratio is 0.20 for the year ending June 30, 2024, a 9.04% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Prestige BioPharma Limited Debt to Equity Ratio for the year ending June 30, 2023 was 0.19, a 1,794.92% change year over year.
Prestige BioPharma Limited Debt to Equity Ratio for the year ending June 30, 2022 was 0.01, a -26.87% change year over year.
Prestige BioPharma Limited Debt to Equity Ratio for the year ending June 30, 2021 was 0.01, a -35.30% change year over year.
Prestige BioPharma Limited Debt to Equity Ratio for the year ending June 30, 2020 was 0.02, a -93.44% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

KSE: 950210.KS

Prestige BioPharma Limited

CEO	Ms. So-Yeon Park
IPO Date	Feb. 9, 2021
Location	Singapore
Headquarters	21 Biopolis Road
Employees	66
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Plastics Vaccines

Description

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is also developing vaccines for COVID-19 virus. The company was incorporated in 2015 and is headquartered in Singapore.

Key trends

Past 5 years